First Head-to-Head of Chemo for Prostate Cancer First Head-to-Head of Chemo for Prostate Cancer
The first head-to-head comparison of two chemotherapies for prostate cancer finds similar survival gains but different toxicity profiles.Medscape Medical News
As they get older, do men with prostate cancer come to regret the treatment decisions they made? A new study of men diagnosed during the mid-1990s indicates that some of them will. Richard Hoffman, a professor of internal medicine and epidemiology at the University of Iowa Carver College of Medicine in Iowa City, led a team that reviewed survey data that men filled out one, two, five, and 15 years after they were treated for prostate cancer. All 934 men included in the study were 75 or younger when diagnosed, each with localized tumors confined to the prostate gland. Approximately 60% of the men had low-risk prostate cance...
Conclusion: This is one of the few studies that have identified the unmet supportive care needs of men receiving hormone therapy for ≥T3 prostate Cancer or worse. The needs are multiple and far-ranging. Implications for Practice: Despite national cancer reforms, unmet supportive care needs persist. The findings from this study may be central in the re-design of future services to optimize men’s quality of life and satisfaction with care. Clinicians are encouraged to use these finding to help them optimize care delivery and individual quality of life.
Researchers from the Albert Einstein College of Medicine have pinpointed how certain nerves drive the growth of prostate cancer using a metabolic 'switch.'
Conclusion: A role for 68Ga-PSMA-I&T PET/CT in primary PCa staging of high-grade disease (GS 8 or more and PSA>10 ng/ml) has been shown. There was a low rate of detection of PSMA-avid metastases in low-grade disease (GS 7 or less and PSA
In conclusion, our findings have identified critical molecular mechanisms involving ERK-mediated ERG activation that could be exploited for therapeutic intervention in ERG-positive prostate cancers.
Conclusion ADT can relieve retention and decrease PVR over a period of time obviating the need for channel transurethral resection of the prostate.
October 19, 2017—(Bronx, NY)—In a study in today’s issue of Science, researchers at Albert Einstein College of Medicine, part ofMontefiore, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels to proliferate. Their earlier research—which first implicated nerves in fueling prostate cancer—has prompted Montefiore-Einstein to conduct a pilot study testing whether beta blockers (commonly used for treating hypertension) can kill cancer cells in tumors of men diagnosed with prostate cancer.
By age 60, you have a 50/50 chance of having a clinically enlarged prostate. And it only gets worse every year. When your prostate isn’t functioning properly, it’s hard to enjoy life. Traditional doctors give you two choices. Go under the knife or you take Big Pharma’s drugs. Either way, you have a good chance of ending up with your manhood on the line… If you have surgery, there’s a big risk you’ll be saying goodbye to your sex life for good. The rate of impotence is a shocking 50 to 60% after prostate surgery.1 Big Pharma’s meds to shrink your prostate are no better. These sy...
Condition: Metastatic Castrate-resistant Prostate (CRPC) Cancer Interventions: Drug: ODM-201; Drug: Enzalutamide Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Not yet recruiting
This study shows why it is important for researchers to consistently take these steps. The authors of the current research make a number of suggestions for additional improvements to the current situation, including that: papers reporting on the discovery of misidentified cell lines need to be clearly labelled so that other researchers can easily find them to make sure they don't "spread" misleading research in their own publications those aiming to clean up the contamination problem should write about the contamination, using social media campaigns and general media coverage to highlight the issue and insp...